Gene Center Munich

Breadcrumb Navigation

Prof. Dr. Marion Subklewe

Prof. Dr. Marion Subklewe



Gene Center
Laboratory for Translational Cancer Immunology
Ludwig-Maximilians-Universität München
Feodor-Lynen-Straße 25
81377 Munich

Room: A 2.04
Phone: +49 (0)89 - 4400 73133

Work group


Professional Experience

since 2017 Head of the Laboratory for
Translational Cancer Immunology
Gene Center Munich
since 2014 Professor for Internal Medicine, 
with focus on Cellular Immunotherapy
University Hospital, LMU Munich,
Department of Medicine III
2012-2017 Head of the Clinical Cooperation Group "Immunotherapy" Helmholtz Zentrum Munich
since 2009 Head of Flow Cytometry,
Laboratory of Leukemia Diagnostics
University Hospital, LMU Munich,
Department of Medicine III,
Prof. Dr. W. Hiddemann
since 2009 Consultant for Hematology / Oncology University Hospital, LMU Munich,
Department of Medicine III,
Prof. Dr. W. Hiddemann
2008-2009 Clinical Fellow Hematology / Oncology University Hospital, LMU Munich,
Department of Medicine III,
Prof. Dr. W. Hiddemann
2000-2007 Clinical Fellow Hematology / Oncology The Charité, Campus Virchow-Klinikum,
Medical Department III, Berlin,
Prof. Dr. B. Dörken
1996-2000 Postdoctoral Fellow, DFG-Scholarship,
Cure for Lymphoma Fellow
Rockefeller University, New York,
Prof. Dr. R. M. Steinman
1995-1996 Residency Internal Medicine University Hospital Tübingen,
Medical Department II,
Hematology / Oncology / Reheumatology,
Prof. Dr. L. Kanz


2014 W2-Professor for Internal Medicine,
with focus on Cellular Immunotherapy
University Hospital, LMU Munich
2007 „Habilitation“ in Internal Medicine Charité, Berlin
2007 Board Certification Hematology / Oncology
2005 Board Certification Internal Medicine
1995 Medical Dissertation University of Cologne,
Department of Internal Medicine,
Hematology / Oncology,
Prof. Dr. V. Diehl
1988-1993 Study of Medicine University of Cologne
1986-1988 Study of Medicine RWTH Aachen

Awards and Honors

2015 M4-Award: Startup support for the development of a novel multispecific antibody derivative
2015 ASH Abstract Achievement Award: Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE Antibody Construct (AMG 330) Mediated Cytotoxicity
2014 DGHO-Poster Prize: Addition of CD200 and Omission of sIgM Improves the Scoring System for the Diagnosis of CLL
2013 Selection for the ASH Highlights: Evaluation of CD33 expression and functional analysis of the CD33/CD3 bispecific antibody AMG 330 activity in primary AML samples
2012 Therese von Bayern-Award
2011 ASH Abstract Achievement Award: A Combined Score of Minimal Residual Disease (MRD) Assessment by Flow Cytometry, Cytogenetic and Molecular Markers As Well As Age Predicts Outcome and Can Potentially Guide MRD-Based Therapy in Acute Myeloid Leukemia
2011 ASH Abstract Achievement Award: Dendritic Cells Matured with a TLR7/8 Agonist Induce T Helper 1 Cell Polarization, Activate NK Cells and Are Thus Highly Suitable for Application in Cancer Immunotherapy
2011 Best Lecturer at the faculty of Medicine at the LMU
2005-2007 Rahel-Hirsch Scholarship at the Charité („Habilitations-Scholarship“)
1999-2000 Cure for Lymphoma Foundation Fellow
1996-1999 Postdoctoral Scholarship of the Deutsche Forschungsgemeinschaft

Additional Functions

  • Spokesman of the Else Kröner Clinician Scientist Programm Cancer Immunotherapy - LMU Munich, fostering the development of clinician scientists in oncology/immunology by a network of expert mentors, protected time for research, seminars and travel support
  • Principal Investigator and Sponsor delegated Person of a prospective Phase I/II I-IT “Active immunotherapy of patients with AML using autologous dendritic cells transfected with RNA encoding leukemia-associated antigens”
  • Principal Investigator of a Phase I Study „A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Acute Myeloid Leukemia“
  • Principle Investigator in multiple Phase I trials (CAR T, T-cell recruiting antibodies), Principle Investigator in multiple Phase II/III trials in leukemia and lymphoma (GMALL, GLSG, DSHNHL)
  • Protocol committee AML Cooperative Group (AML-CG)
  • Member of the Organizing Committee of the International Symposium “Acute Leukemias” 2011; 2013; 2015; 2017
  • Certification (2011) and Akkreditation Flow Cytometry (2012) within the Laboratory of Leukemia Diagnostics
  • Collaborative Research Activities – Bavarian Immunotherapy Network, Helmholtz Alliance for Immunotherapy, Deutsches Konsortium für Translationale Krebsforschung, Munich Immunotherapy Consortium (MITC), Elitenetzwerk Bayern International Graduate School “Immunotargeting of Cancer”, SFB1243 “Cancer Evolution”, Else-Kröner Fresenius Forschungskolleg “Cancer Immunotherapy”
  • Grant Reviews - Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; José-Carreras Stiftung; Wilhelm Sander Stiftung; Cancer Research UK; Leukemia and Lymphoma; OeGHO, Dutch Cancer Society, Wordwide Cancer Research
  • Manuscript Reviews - Blood, Leukemia, Lancet Hematology, NEJM, PlosOne, J International Immunology, Journal of Hematology & Oncology; Haematologica; British Journal of Hematology
  • Membership - Bund deutscher Internisten (BdI); European Association for Hematology (EHA); American Society for Hematology (ASH); Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO); Society for Immunotherapy of Cancer (SITC)
  • Member of the “Research committee (Forschungskommission)” Klinikum der Universität München, member of several Thesis Advisory Committees